Shift in capital market! From M&A to VC and strategic partnerships Will Europe see a U-turn of venture capital investment in 2013? More and Big Pharma companies are seeking to fill their pipelines and thus launch Corporate venture funds. The shift in investors is also accompanied by a shift in VC models. Beside classical VC, a number of new measures have been tested by Biotech companies – some of them successful. EuroBiotechNews is analysing the most promising. This special presents insights from industry heavyweights. It is composed to meet the interests of investors, company leaders, business development and other capital market experts – in brief: the perfect opportunity to target your audience and get your message across!
